In re ACTOS Antitrust Litigation

  1. April 14, 2025

    Takeda Gets Actos Case Paused For Class Cert. Review

    A New York federal court has paused a lawsuit accusing Takeda Pharmaceuticals of inflating the price of its diabetes treatment, Actos, by delaying the entry of generic alternatives, and took a scheduled July trial off the calendar, as the company appeals a class certification ruling.

  2. April 09, 2025

    2nd Circ. Allows Takeda To Appeal Actos Antitrust Class Cert.

    A split Second Circuit will allow Takeda Pharmaceuticals Co. to immediately appeal a New York federal judge's ruling certifying two classes of direct purchasers and end payors in consolidated antitrust actions accusing the company of unlawfully inflating the price of its diabetes treatment Actos by delaying the entry of generic alternatives.

  3. April 01, 2025

    Takeda Antitrust Trial Over Actos Generics Set For July

    A New York federal court refused a bid from Takeda Pharmaceuticals Co. to escape a long-running case accusing it of unlawfully delaying generic versions of its diabetes treatment Actos and scheduled a trial to start in July.

  4. September 30, 2024

    Takeda End Payors, Direct Buyers Win Antitrust Class Cert.

    A New York federal judge Monday adopted a magistrate judge's recommendation to certify two classes of direct purchasers and end payors in consolidated antitrust actions accusing Takeda Pharmaceuticals Co. of unlawfully inflating the price of its diabetes treatment Actos by delaying entry of generic alternatives.

  5. August 09, 2024

    Takeda Should Face Certified Antitrust Classes, Judge Says

    A New York federal judge on Friday recommended certifying two classes of direct purchasers and end payors in consolidated antitrust actions accusing Takeda Pharmaceuticals Co. of unlawfully inflating the price of its diabetes treatment Actos by delaying entry of generic alternatives.

  6. January 29, 2020

    Takeda Gets Go-Ahead To Appeal Actos Rulings At 2nd Circ.

    A New York federal judge has given pharmaceutical firm Takeda permission to appeal to the Second Circuit two decisions that preserved allegations it delayed the entry of generic alternatives to diabetes treatment Actos.

  7. October 23, 2018

    Takeda Tries Again To Shake Actos Antitrust Claims

    Takeda Pharmaceutical Co. told a New York federal judge Tuesday that it's common practice for drugmakers to draw loose connections between their products and their intellectual property in a national register of government-approved drugs, arguing that an antitrust lawsuit allegedly painting that list as scripture should be dismissed for a second time.

  8. October 22, 2015

    Actos Buyers Head To 2nd Circ. After Pay-For-Delay Suit Nixed

    Buyers of the diabetes drug Actos on Thursday told a New York federal judge, who last month dismissed their pay-for-delay suit against Takeda and five generic drugmakers, that they are appealing his decision to the Second Circuit.

  9. September 23, 2015

    Actos Pay-For-Delay Class Action Gets The Boot

    Takeda and five generic-drug makers escaped a pay-for-delay suit over the diabetes drug Actos when a New York federal judge ruled Tuesday that drug buyers relied on too broad an interpretation of the U.S. Supreme Court's decision in Federal Trade Commission v. Actavis Inc.

  10. July 27, 2015

    Drug Cos. Say Rulings Don't Boost Actos Pay-For-Delay Suit

    Three recent high-profile antitrust rulings should have no bearing on a pay-for-delay suit over Takeda Pharmaceutical Co.'s diabetes drug Actos, the defendants told a New York federal judge Friday, disputing plaintiffs' suggestion that the appellate decisions bolster their argument.